Aldeyra's eye drug fails piv­otal test in pa­tients with rare, in­flam­ma­to­ry dis­ease

Months af­ter eye drug de­vel­op­er Aldeyra Ther­a­peu­tics tast­ed Phase III suc­cess, it has stum­bled in an­oth­er late-stage study with its lead ex­per­i­men­tal drug.

The eye …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER